<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E9AC78C-5AED-4387-A74B-E8561E9FE1C9"><gtr:id>2E9AC78C-5AED-4387-A74B-E8561E9FE1C9</gtr:id><gtr:name>Velindre Cancer Centre</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E9AC78C-5AED-4387-A74B-E8561E9FE1C9"><gtr:id>2E9AC78C-5AED-4387-A74B-E8561E9FE1C9</gtr:id><gtr:name>Velindre Cancer Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A56659BA-683E-45AE-AB1C-DA0690F1DA7D"><gtr:id>A56659BA-683E-45AE-AB1C-DA0690F1DA7D</gtr:id><gtr:firstName>Awen</gtr:firstName><gtr:surname>Gallimore</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/61648DA6-2119-42A3-AC98-EA8148C4A094"><gtr:id>61648DA6-2119-42A3-AC98-EA8148C4A094</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:surname>Ager</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL008742%2F1"><gtr:id>8C68A5B9-20E1-479B-8F35-B6918C24AA99</gtr:id><gtr:title>Dissecting the impact of L-selectin on T lymphocyte dependent tumour immunity</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L008742/1</gtr:grantReference><gtr:abstractText>The harnessing of one's own immune system to treat a cancer, termed tumour immunotherapy, is an extremely attractive proposition because of the potential for combining high selectivity with low toxicity. Tumour immunotherapy has progressed significantly in recent years with improved understanding of how to boost the normally weak immune response to tumours. Nevertheless, there is considerable need for more improvements to ensure this form of treatment is more widely and effectively applied. Successful immunotherapy depends on immune cells, such as killer T lymphocytes, becoming activated and homing to the tumour. However, tumour blood vessels limit access of T lymphocytes to the tumour. We have found that T lymphocytes are better equipped to control tumour growth when they express the homing molecule L-selectin. We predict this is because L-selectin expression factilitates access of killer T cells to the tumour where they can deliver their lethal hit. The aim of this proposal is to study the properties of these L-selectin enhanced T lymphocytes and to determine whether they could be used to treat tumours. The potential long-term benefit of this work is that it will direct novel strategies for improving the clinical application of tumour immunotherapy.</gtr:abstractText><gtr:technicalSummary>T lymphocyte infiltration of tumours correlates with improved outcome in patients. However, tumours actively suppress T cell recruitment by inhibiting the expression of homing associated cell adhesion molecules and chemokines on blood vessels in draining lymph nodes and within the tumour. The overall effect is to limit priming of T cells to tumour derived antigens in lymph nodes draining the tumour. Even if T cells are primed, recruitment into the tumour will be restricted because tumour blood vessels fail to support T lymphocyte homing. Strategies that boost the localisation of effector T cells capable of tumour destruction within the tumour may improve the efficacy of immunotherapies to control tumour growth. Several studies link the expression of the leucocyte specific homing molecule L-selectin/CD62L and tumour growth but the underlying mechanisms are unknown. Since L-selectin is an essential lymph node homing molecule, the role of L-selectin in regulating tumour immunity may be to facilitate T cell priming and differentiation in response to tumour derived antigens in draining lymph nodes. However, studies using L-selectin knockout mice have shown that reduced control of tumour growth in these mice is not simply due to lack of cytotoxic T lymphocyte (CTL) generation but correlated with a markedly reduced recruitment of leucocyes into the tumour. This highlights an important role for L-selectin in regulating leucocyte recruitment into tumours. We have found that the rapid growth of primary tumours in L-selectin deficient mice is reduced by maintaining expression of L-selectin on T lymphocytes. These data demonstrate that T cell expressed L-selectin controls tumour immunity and reveal a novel way of promoting tumour immunity by altering expression of homing molecules on T cells. The aim of this proposal is to study the properties of these L-selectin enhanced T lymphocytes and to determine whether they could be used to treat tumours.</gtr:technicalSummary><gtr:potentialImpactText>The cell adhesion molecules that regulate leucocyte recruitment from the bloodstream to sites of infection, immunity and inflammation are targets for immunotherapy but the idea of promoting immune responses by manipulating immune cell homing is relatively unexplored. This research will benefit academics and biotechnology industries interested in how immune responses are regulated by immune cell trafficking and provide training for postgraduate and postdoctoral science and medical students. It also has educational benefit to undergraduate and school students in understanding the complex interplay between the immune system and cancer. There is currently a lot of interest in the use of immunotherapy to control cancers and this research will be of general interest to the public. 
Identification of strategies to improve the effectiveness of immunotherapies will contribute to improving the nation's health by combating chronic debilitating diseases such as cancer, autoimmunity and chonic infection. Training of Ph.D. students and post-doctoral scientists in leucocyte trafficking expands the expertise base within the UK and internationally. Participation in public lectures, open days for schools, work experience placements for school and undergraduate students from within the UK and Europe disseminates ongoing research in Cardiff into immunotherapy.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-12-08</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-04-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>416232</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Velindre Cancer Centre</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Low dose irradiation of T cells and cancer immunotherapy</gtr:description><gtr:id>6DBCBF80-E5B6-4E91-A6BD-53D279412699</gtr:id><gtr:impact>Spary LK, Al-Taei S, Salimu J, Cook AD, Ager A, Watson HA, Clayton A, Staffurth J, Mason MD, Tabi Z. (2014) Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. J Immunol. 192:3101-10; doi: 10.4049/jimmunol.1302736</gtr:impact><gtr:outcomeId>58c140569b1997.65336395-1</gtr:outcomeId><gtr:partnerContribution>Dr Zsuzsanni Tabi provided technical and practical assistance in the use of low dose irradiation of mouse T cells.</gtr:partnerContribution><gtr:piContribution>Determining the impact of low dose irradiation of T cells on adoptive cell therapy for solid cancers in experimental mice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Laboratory of Immunology</gtr:department><gtr:description>Lung T cell responses to IL-1 and LPS</gtr:description><gtr:id>2DA62DE8-EECD-415F-BE02-8AE6F0B7CD61</gtr:id><gtr:impact>Caucheteux S M, Hu-Li, Mohammed R, Ager A and Paul W E. Cytokine Regulation of Lung Th17 Response to Airway Immunization using LPS Adjuvant. (2016) Mucosal Immunol. doi: 10.1038/mi.2016.54</gtr:impact><gtr:outcomeId>58c143565bf901.57660831-1</gtr:outcomeId><gtr:partnerContribution>In depth analysis of cytokine and cellular responses in virus-infected and adjuvant challenged mouse lungs.</gtr:partnerContribution><gtr:piContribution>Analysis of the impact of LPS on pulmonary cytokine production and analysis of lung histology</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>L-selectin and anti-viral immunity</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D48D5728-16C6-40D3-8B4B-92E67A7E4FB9</gtr:id><gtr:impact>Press release on 'Flu-tackling molecule found by Cardiff University scientists' was picked up by the BBC and displayed on BBC website.</gtr:impact><gtr:outcomeId>58c1356becd7c5.80981503</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/uk-wales-south-east-wales-35373730</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview  for Pythagorus' Trousers on Radio Cardiff</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BFA59D2C-6C80-44D3-8A88-7D502A028A47</gtr:id><gtr:impact>Question and answer session in which Rhys Phillip questioned Dr Ann Ager about her recent findings related to combating virus infections. Broadcast in a weekly science and technology radio show on Radio Cardiff sponsored by Airbus Group.</gtr:impact><gtr:outcomeId>58c137b9cf7366.94181793</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science in Health live</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9A2F76C9-FDD1-4C64-BB3A-FB8C30FFC8EB</gtr:id><gtr:impact>More than 800 year 12 pupils considering medicine and/or science careers attended a 2-day visit to participate in Science in Health-Live (SIH-L)organised by the School of Medicine, Cardiff University. It involves more than 150 members of staff, from postgraduates to Professors, who provide a diverse range of short talks, science theatre, stand-up comedy, a science quiz and interactive exhibits and laboratory tours. Dr Ager presented a lecture on 'Directing the traffic: how to leucocytes know where to go in the body?'
Throughout the day, interactive polling allows the students to text in questions they may have concerning entry to university, career prospects in science/medicine and individuals within the School respond to these questions. The closing event of the day profiles the careers of leading clinical and non-clinical investigators in which each investigator briefly explains how their science, education and personal interests have led them down distinct career paths. SIH Live aims to excite students about science by allowing them access to Cardiff University research that is having an impact upon medical and clinical practice worldwide. We further aim to inspire and inform secondary school students seeking career opportunities in biomedical science and medicine.Dr SIH Live aims to excite students about science by allowing them access to Cardiff University research that is having an impact upon medical and clinical practice worldwide. We further aim to inspire and inform secondary school students seeking career opportunities in biomedical science and medicine.</gtr:impact><gtr:outcomeId>58c13d102941b9.37658713</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ystradown WI</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D02A739A-2652-47D3-857D-2B26DEC87B93</gtr:id><gtr:impact>Dr Ager gave a lay overview of her recent studies on 'T cells- a discovery' to 25 members of the Women's Institute int the area where she resides.</gtr:impact><gtr:outcomeId>58c13de809fe69.94226467</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>82CCBB11-82B6-4247-9DEC-2A7AB71ED718</gtr:id><gtr:title>Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of na&amp;iuml;ve CD4+ T cells via blood vessels and lymphatics.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>58c1323963bcd3.51067696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AE88F47-CE01-4AB5-9892-EC114FEC9C3C</gtr:id><gtr:title>Cytokine regulation of lung Th17 response to airway immunization using LPS adjuvant.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bbbc4da9bb6f9cb7b2c03ce0a34c4df"><gtr:id>6bbbc4da9bb6f9cb7b2c03ce0a34c4df</gtr:id><gtr:otherNames>Caucheteux SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>58c130d120c627.20825677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4CD7A4F-9CF3-4FAE-BB8E-55602A742AF0</gtr:id><gtr:title>High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f47542d1c94303308e999c6ef51fad6"><gtr:id>7f47542d1c94303308e999c6ef51fad6</gtr:id><gtr:otherNames>Bento DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>58c131d9f060d5.97610034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BE933C3-DC1C-4B89-95ED-14D81400E3D9</gtr:id><gtr:title>TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cell biology international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0dcc6ab1e99eeb980f9c7f916545f9ca"><gtr:id>0dcc6ab1e99eeb980f9c7f916545f9ca</gtr:id><gtr:otherNames>Gawel-Beben K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1065-6995</gtr:issn><gtr:outcomeId>5a2fd5aa1bb560.59004278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C58013B-FC3E-472F-93F9-ACF122EFE4B4</gtr:id><gtr:title>L-selectin Is Essential for Delivery of Activated CD8(+) T Cells to Virus-Infected Organs for Protective Immunity.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1a307f3ce3405ae2c1390ecf35faa8a"><gtr:id>a1a307f3ce3405ae2c1390ecf35faa8a</gtr:id><gtr:otherNames>Mohammed RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d53e4a50033.71286353</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D41C081-6EC9-460E-B09A-F8B334EA1A62</gtr:id><gtr:title>Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81535c1c3634806911a3fcf244b4293b"><gtr:id>81535c1c3634806911a3fcf244b4293b</gtr:id><gtr:otherNames>Spary LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>58c13204bfbb85.16950534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9F2069F-C1F2-4F90-8177-79C36CA1D9C6</gtr:id><gtr:title>A distinct chemokine axis does not account for enrichment of Foxp3(+) &amp;nbsp;CD4(+) T cells in carcinogen-induced fibrosarcomas.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>58c131ac519d60.12267543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94D734F4-9142-494D-AF87-A51F94B7081A</gtr:id><gtr:title>Understanding high endothelial venules: Lessons for cancer immunology.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/960d018d17a8ce1d592bd61336ac7014"><gtr:id>960d018d17a8ce1d592bd61336ac7014</gtr:id><gtr:otherNames>Ager A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>5675e818a795f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41E5C75B-AE45-427A-8A1B-6754069A5E00</gtr:id><gtr:title>Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/960d018d17a8ce1d592bd61336ac7014"><gtr:id>960d018d17a8ce1d592bd61336ac7014</gtr:id><gtr:otherNames>Ager A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>585d51176f5f19.36650947</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72866BC5-D60A-4C50-B1C6-965BCB392BFE</gtr:id><gtr:title>Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/639b9cabc30209175d7feb03d9eaf8c2"><gtr:id>639b9cabc30209175d7feb03d9eaf8c2</gtr:id><gtr:otherNames>Colbeck EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a679418dba278.70489561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDEFBA18-9451-4A23-80A1-4A5ACDB86769</gtr:id><gtr:title>High Endothelial Venules and Other Blood Vessels: Critical Regulators of Lymphoid Organ Development and Function.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/960d018d17a8ce1d592bd61336ac7014"><gtr:id>960d018d17a8ce1d592bd61336ac7014</gtr:id><gtr:otherNames>Ager A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>58c1304e189410.28846918</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC61661A-2DDF-49BC-85EC-09EE37E6B47F</gtr:id><gtr:title>SHP-1: the next checkpoint target for cancer immunotherapy?</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/904b19b2f1edd41f25aeec6846641b4a"><gtr:id>904b19b2f1edd41f25aeec6846641b4a</gtr:id><gtr:otherNames>Watson HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>585d511ab17246.44659642</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L008742/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>